Mereo Biopharma Group Plc ADR (MREO)

$4.38 +0.03 (0.69%)
Market Cap 530.17M
Revenue (ttm) 10.00M
Net Income (ttm) -29.47M
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume 28,075
Avg Vol 812,584
Day's Range N/A - N/A
Shares Out 140.26M
Stochastic %K 30%
Beta 0.88
Analysts Strong Sell
Price Target $6.80

Company Profile

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab, an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for use in the treatment of tumors. The company is also developing Navicixizumab, which has completed Phase 1b clinical trials for the treatment of the late line ovarian ca...

Industry: Biotechnology
Sector: Healthcare
Phone: 44 33 3023 7300
Address:
One Cavendish Place, 4th Floor, London, United Kingdom
Berakhot
Berakhot Aug. 6 at 6:25 PM
$MREO added, will keep adding this level or below.
0 · Reply
Mjcwo
Mjcwo Aug. 6 at 6:15 PM
💥 $MREO loaded with cash (~$90M), no debt, no need to dilute. Float is tight, volume creeping up. Biggest bull case? Partnership PR could drop any day. Mgmt has hinted — and when it hits, this rips. Low risk, high reward setup. One deal and shorts get cooked. 🧨 $MRTX $IMMU
1 · Reply
douglas98
douglas98 Aug. 6 at 2:26 PM
$MREO a very familiar story. Within 18 months there will be a reverse split and raise and there is no partnership there was never any partnership. Denise is doing what countless other ceos have done and is bleeding a dying horse dry
1 · Reply
douglas98
douglas98 Aug. 6 at 1:35 PM
$MREO the writing looks to be on the wall here. So sad. Such great potential ruined by Denise. 5 years been hearing about the mythical partnership that’s just around the corner
0 · Reply
Berakhot
Berakhot Aug. 6 at 12:02 PM
$MREO Double bottom potential, see if it rebounds.
0 · Reply
OutperformGER
OutperformGER Aug. 6 at 4:23 AM
$MREO 👇
0 · Reply
douglas98
douglas98 Aug. 5 at 10:16 PM
$MREO the drip is dripping. Pummelled today
0 · Reply
lidopete
lidopete Aug. 5 at 8:11 PM
$MREO $RARE Emil D. Kakkis, M.D., Ph.D., chief executive officer and president of Ultragenyx. “We are excited for the potential of UX143 in osteogenesis imperfecta to reduce fractures and meaningfully improve patients’ bone health. " Results around the end of this year per release.
0 · Reply
Mjcwo
Mjcwo Aug. 5 at 3:13 PM
$MREO is coiled and ready to rip. Massive upside when partnership news hits — could drop any time. Strong support base locked in. This is a sleeper monster in the making. Watch it move. 👀🔥 $XBI $TNXP $IXHL
0 · Reply
Newcar
Newcar Aug. 5 at 12:40 PM
$MREO Sooner or later it will explode. If there were to be a speculative collapse in the meantime, I would buy more.👍👍👍
0 · Reply
Latest News on MREO
Mereo BioPharma: Buy Rating Despite No Early Study Completion Of Setrusumab For OI

Jul 10, 2025, 3:15 PM EDT - 27 days ago

Mereo BioPharma: Buy Rating Despite No Early Study Completion Of Setrusumab For OI

Mereo BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Highlights

May 13, 2025, 7:30 AM EDT - 3 months ago

Mereo BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Highlights

Mereo BioPharma Reports Full Year 2024 Financial Results and Provides Corporate Highlights

Mar 26, 2025, 7:30 AM EDT - 4 months ago

Mereo BioPharma Reports Full Year 2024 Financial Results and Provides Corporate Highlights

Mereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Healthcare Conference

Mar 5, 2025, 7:30 AM EST - 5 months ago

Mereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Healthcare Conference

Mereo BioPharma Provides Update on Lead Clinical Programs

Jan 12, 2025, 11:05 AM EST - 7 months ago

Mereo BioPharma Provides Update on Lead Clinical Programs

Mereo BioPharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 7, 2025, 7:30 AM EST - 7 months ago

Mereo BioPharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Mereo BioPharma: Setrusumab Chugs Along With Possible Inflection Points

Nov 26, 2024, 1:36 PM EST - 9 months ago

Mereo BioPharma: Setrusumab Chugs Along With Possible Inflection Points

Mereo BioPharma to Participate in Fireside Chat at the Jefferies London Healthcare Conference

Nov 14, 2024, 7:30 AM EST - 9 months ago

Mereo BioPharma to Participate in Fireside Chat at the Jefferies London Healthcare Conference

Mereo BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 12, 2024, 7:30 AM EST - 9 months ago

Mereo BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Mereo BioPharma to Participate in Fireside Chat at the 2024 Cantor Global Healthcare Conference

Sep 12, 2024, 5:35 PM EDT - 11 months ago

Mereo BioPharma to Participate in Fireside Chat at the 2024 Cantor Global Healthcare Conference

Mereo BioPharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 13, 2024, 8:00 AM EDT - 1 year ago

Mereo BioPharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Mereo BioPharma Announces Pricing of $50 Million Underwritten Registered Direct Offering of American Depository Shares, Priced At-the-Market

Jun 14, 2024, 7:50 AM EDT - 1 year ago

Mereo BioPharma Announces Pricing of $50 Million Underwritten Registered Direct Offering of American Depository Shares, Priced At-the-Market

Mereo BioPharma to Participate in Fireside Chat at the Jefferies Global Healthcare Conference

May 30, 2024, 7:30 AM EDT - 1 year ago

Mereo BioPharma to Participate in Fireside Chat at the Jefferies Global Healthcare Conference

Mereo BioPharma Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 15, 2024, 4:01 PM EDT - 1 year ago

Mereo BioPharma Reports First Quarter 2024 Financial Results and Provides Corporate Update

Mereo BioPharma to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference

Apr 3, 2024, 7:30 AM EDT - 1 year ago

Mereo BioPharma to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference

Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update

Mar 27, 2024, 4:01 PM EDT - 1 year ago

Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update

Newer Treatments In Alpha-1 Antitrypsin Deficiency: $2.5 Billion/Year Market Size By 2032

Mar 14, 2024, 5:34 PM EDT - 1 year ago

Newer Treatments In Alpha-1 Antitrypsin Deficiency: $2.5 Billion/Year Market Size By 2032

KRRO KRYS TAK WVE

Mereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Biopharma Conference

Mar 5, 2024, 7:30 AM EST - 1 year ago

Mereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Biopharma Conference

Mereo BioPharma Provides Update on Pipeline Progress and Corporate Developments

Jan 8, 2024, 7:00 AM EST - 1 year ago

Mereo BioPharma Provides Update on Pipeline Progress and Corporate Developments

Mereo BioPharma Reports on Recent Program Developments and Provides Financial Update

Oct 23, 2023, 4:01 PM EDT - 1 year ago

Mereo BioPharma Reports on Recent Program Developments and Provides Financial Update

Mereo BioPharma to Participate in Fireside Chat at the 2023 Cantor Global Healthcare Conference

Sep 21, 2023, 7:00 AM EDT - 2 years ago

Mereo BioPharma to Participate in Fireside Chat at the 2023 Cantor Global Healthcare Conference

Mereo BioPharma Reports Interim Financial Results for the Six Months Ended June 30, 2023 and Provides Corporate Update

Sep 7, 2023, 7:30 AM EDT - 2 years ago

Mereo BioPharma Reports Interim Financial Results for the Six Months Ended June 30, 2023 and Provides Corporate Update

Mereo BioPharma to Present at the Jefferies Healthcare Conference

May 31, 2023, 7:00 AM EDT - 2 years ago

Mereo BioPharma to Present at the Jefferies Healthcare Conference

Phase 2 Data from “ASTRAEUS” Trial of Mereo BioPharma's Alvelestat in Alpha-1 Antitrypsin Deficiency-associated Lung Disease Presented at the 2023 American Thoracic Society International Conference

May 23, 2023, 1:43 PM EDT - 2 years ago

Phase 2 Data from “ASTRAEUS” Trial of Mereo BioPharma's Alvelestat in Alpha-1 Antitrypsin Deficiency-associated Lung Disease Presented at the 2023 American Thoracic Society International Conference

Mereo BioPharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

May 8, 2023, 12:46 PM EDT - 2 years ago

Mereo BioPharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

Mereo BioPharma Announces Listing Transfer to Nasdaq Capital Market

May 5, 2023, 4:06 PM EDT - 2 years ago

Mereo BioPharma Announces Listing Transfer to Nasdaq Capital Market

Mereo BioPharma Reports Full Year 2022 Financial Results and Recent Highlights

Mar 28, 2023, 4:30 PM EDT - 2 years ago

Mereo BioPharma Reports Full Year 2022 Financial Results and Recent Highlights

Mereo BioPharma Provides Regulatory Updates on Alvelestat for the Treatment of Alpha-1-Antitrypsin Deficiency-Associated Lung Disease

Mar 21, 2023, 6:30 AM EDT - 2 years ago

Mereo BioPharma Provides Regulatory Updates on Alvelestat for the Treatment of Alpha-1-Antitrypsin Deficiency-Associated Lung Disease

Mereo BioPharma to Participate in Fireside Chat at the SVB Securities Global Biopharma Conference

Feb 8, 2023, 7:00 AM EST - 2 years ago

Mereo BioPharma to Participate in Fireside Chat at the SVB Securities Global Biopharma Conference

Mereo BioPharma Received Notification of Nasdaq Minimum Bid Price Deficiency

Nov 2, 2022, 4:01 PM EDT - 3 years ago

Mereo BioPharma Received Notification of Nasdaq Minimum Bid Price Deficiency

Mereo BioPharma Reaches Cooperation Agreement with Rubric Capital Management

Oct 28, 2022, 7:00 AM EDT - 3 years ago

Mereo BioPharma Reaches Cooperation Agreement with Rubric Capital Management

Mereo BioPharma to Host Alvelestat R&D Update Call on October 31, 2022

Oct 24, 2022, 4:30 PM EDT - 3 years ago

Mereo BioPharma to Host Alvelestat R&D Update Call on October 31, 2022

Mereo BioPharma Files Shareholder Circular for Upcoming General Meeting

Oct 21, 2022, 7:00 AM EDT - 3 years ago

Mereo BioPharma Files Shareholder Circular for Upcoming General Meeting

Rubric Capital Management Comments on Mereo BioPharma Updated Operating Plan

Oct 18, 2022, 11:58 AM EDT - 3 years ago

Rubric Capital Management Comments on Mereo BioPharma Updated Operating Plan

Mereo BioPharma Announces Updated Operating Plan to Maximize Shareholder Value

Oct 18, 2022, 7:00 AM EDT - 3 years ago

Mereo BioPharma Announces Updated Operating Plan to Maximize Shareholder Value

Mereo BioPharma Receives FDA Fast Track Designation for Alvelestat for Treatment of Alpha-1 Antitrypsin Deficiency (AATD)-associated Lung Disease

Oct 17, 2022, 7:00 AM EDT - 3 years ago

Mereo BioPharma Receives FDA Fast Track Designation for Alvelestat for Treatment of Alpha-1 Antitrypsin Deficiency (AATD)-associated Lung Disease

Mereo BioPharma Confirms Receipt of a Valid Notice Requiring it to Convene a General Meeting of Shareholders

Oct 3, 2022, 5:00 PM EDT - 3 years ago

Mereo BioPharma Confirms Receipt of a Valid Notice Requiring it to Convene a General Meeting of Shareholders

Rubric Capital Management Increases Slate of Proposed Mereo BioPharma Director Nominees to Five

Oct 3, 2022, 9:00 AM EDT - 3 years ago

Rubric Capital Management Increases Slate of Proposed Mereo BioPharma Director Nominees to Five

Mereo BioPharma Offered to Settle Proxy Contest with Rubric Capital Management by Putting Rubric Principal and Second New Director on the Board

Sep 26, 2022, 7:00 AM EDT - 3 years ago

Mereo BioPharma Offered to Settle Proxy Contest with Rubric Capital Management by Putting Rubric Principal and Second New Director on the Board

Mereo BioPharma: An Activist Pressure With A Potentially Significant Upside

Sep 22, 2022, 1:45 PM EDT - 3 years ago

Mereo BioPharma: An Activist Pressure With A Potentially Significant Upside

Rubric Capital Management Issues Open Letter to Mereo BioPharma Shareholders

Sep 14, 2022, 9:00 AM EDT - 3 years ago

Rubric Capital Management Issues Open Letter to Mereo BioPharma Shareholders

Mereo BioPharma Reports Clinical Update and Interim Biomarker Analysis Presented at ESMO 2022 from ACTIVATE Phase 1b/2 Open Label Study of Etigilimab (Anti-TIGIT Antibody MPH-313) plus Nivolumab (Anti-PD-1 Antibody) in Solid Tumors

Sep 12, 2022, 8:00 AM EDT - 3 years ago

Mereo BioPharma Reports Clinical Update and Interim Biomarker Analysis Presented at ESMO 2022 from ACTIVATE Phase 1b/2 Open Label Study of Etigilimab (Anti-TIGIT Antibody MPH-313) plus Nivolumab (Anti-PD-1 Antibody) in Solid Tumors

Mereo BioPharma Sends Letter to Rubric Capital Management

Aug 31, 2022, 7:00 AM EDT - 3 years ago

Mereo BioPharma Sends Letter to Rubric Capital Management

Why Mereo BioPharma Shares Are Jumping Today

Jun 17, 2022, 10:39 AM EDT - 3 years ago

Why Mereo BioPharma Shares Are Jumping Today

AstraZeneca weighing bid for Mereo BioPharma: report

Jun 17, 2022, 3:44 AM EDT - 3 years ago

AstraZeneca weighing bid for Mereo BioPharma: report

AZN

Mereo BioPharma Announces the Presentation of Updated Data From a Phase 1b/2 Study of Etigilimab as a Poster at the 2022 American Society of Clinical Oncology Annual Meeting

May 26, 2022, 5:05 PM EDT - 3 years ago

Mereo BioPharma Announces the Presentation of Updated Data From a Phase 1b/2 Study of Etigilimab as a Poster at the 2022 American Society of Clinical Oncology Annual Meeting

Mereo BioPharma Shares Jump After Encouraging Alvelestat Data In Lung Disease

May 9, 2022, 7:47 AM EDT - 3 years ago

Mereo BioPharma Shares Jump After Encouraging Alvelestat Data In Lung Disease

Mereo BioPharma to Host Conferene Call Highlighting Top-line Clinical Data from “ASTRAEUS” Phase 2 Study of Alvelestat

May 6, 2022, 5:12 PM EDT - 3 years ago

Mereo BioPharma to Host Conferene Call Highlighting Top-line Clinical Data from “ASTRAEUS” Phase 2 Study of Alvelestat

Berakhot
Berakhot Aug. 6 at 6:25 PM
$MREO added, will keep adding this level or below.
0 · Reply
Mjcwo
Mjcwo Aug. 6 at 6:15 PM
💥 $MREO loaded with cash (~$90M), no debt, no need to dilute. Float is tight, volume creeping up. Biggest bull case? Partnership PR could drop any day. Mgmt has hinted — and when it hits, this rips. Low risk, high reward setup. One deal and shorts get cooked. 🧨 $MRTX $IMMU
1 · Reply
douglas98
douglas98 Aug. 6 at 2:26 PM
$MREO a very familiar story. Within 18 months there will be a reverse split and raise and there is no partnership there was never any partnership. Denise is doing what countless other ceos have done and is bleeding a dying horse dry
1 · Reply
douglas98
douglas98 Aug. 6 at 1:35 PM
$MREO the writing looks to be on the wall here. So sad. Such great potential ruined by Denise. 5 years been hearing about the mythical partnership that’s just around the corner
0 · Reply
Berakhot
Berakhot Aug. 6 at 12:02 PM
$MREO Double bottom potential, see if it rebounds.
0 · Reply
OutperformGER
OutperformGER Aug. 6 at 4:23 AM
$MREO 👇
0 · Reply
douglas98
douglas98 Aug. 5 at 10:16 PM
$MREO the drip is dripping. Pummelled today
0 · Reply
lidopete
lidopete Aug. 5 at 8:11 PM
$MREO $RARE Emil D. Kakkis, M.D., Ph.D., chief executive officer and president of Ultragenyx. “We are excited for the potential of UX143 in osteogenesis imperfecta to reduce fractures and meaningfully improve patients’ bone health. " Results around the end of this year per release.
0 · Reply
Mjcwo
Mjcwo Aug. 5 at 3:13 PM
$MREO is coiled and ready to rip. Massive upside when partnership news hits — could drop any time. Strong support base locked in. This is a sleeper monster in the making. Watch it move. 👀🔥 $XBI $TNXP $IXHL
0 · Reply
Newcar
Newcar Aug. 5 at 12:40 PM
$MREO Sooner or later it will explode. If there were to be a speculative collapse in the meantime, I would buy more.👍👍👍
0 · Reply
Mjcwo
Mjcwo Aug. 4 at 5:48 PM
💥 $PHRRF – AUGUST 9 FDA DECISION INCOMING 💥 Low float. Fully funded. No dilution coming. 🗓️ AUGUST 9 = Binary catalyst. Approval makes $PHRRF the only FDA-approved racemic ketamine supplier. 5x+ potential overnight. Compounded clinics out. PharmaTher takes the market. Massive upside ahead. Don’t forget: 🔬 $MREO – partnership rumors heating up 🧠 $INMB – needs to run, coiling. 💉 $NRXP – ketamine peer, trailing behind
1 · Reply
iaconi
iaconi Aug. 4 at 4:35 PM
$MREO +10к shares at 1,65$, let see!
0 · Reply
Mjcwo
Mjcwo Aug. 4 at 3:26 PM
$INMB amazing news here…should be $5 today, let’s see…loading $MREO when it’s quiet, won’t last long.
0 · Reply
EddieH2020
EddieH2020 Aug. 2 at 4:52 PM
$MREO Bought in this past week at $1.74 after not holding for a long time. Ready for year end
0 · Reply
Mjcwo
Mjcwo Aug. 2 at 12:05 AM
🚨 $TNXP getting ready for liftoff 🔥 FDA decision Aug 15 — no AdCom, clean setup, and not priced in. Positioning now for the run-up + potential early approval. Let’s have some fun the next few weeks 🎯 Meanwhile… quietly loading $MREO & $INMB — both are sleeping giants. Watch for stealth PR drops to snap them back on trend. Accumulating all I can before the crowd wakes up 👀💥
0 · Reply
Mjcwo
Mjcwo Aug. 1 at 1:10 PM
$MREO Low float, strong biotech pipeline, and potential near-term catalysts on the horizon. Upside will be explosive when lpartnership news hits. Watching closely.
0 · Reply
douglas98
douglas98 Aug. 1 at 11:10 AM
$MREO getting hammered PM. Looks destined for a drip back to where it was in 2021
2 · Reply
cheetohottaki
cheetohottaki Jul. 31 at 8:03 PM
$MREO nightmare
0 · Reply
Newcar
Newcar Jul. 31 at 5:17 PM
$MREO one day this will explode 👍
0 · Reply
LDT79
LDT79 Jul. 31 at 2:01 PM
$MREO do something - fuck!
1 · Reply
Newcar
Newcar Jul. 30 at 9:08 AM
$MREO you will see that one of these days it will suddenly open with a +50%-70%....
3 · Reply
Orhidee
Orhidee Jul. 29 at 8:34 PM
$MREO we held well considering the market
0 · Reply